Loading…
← CockpitCompetitor Analysis › ALK-B.CO ALK-abello A/S Class BOpen in the cockpit ↗

ALK-abello A/S Class BALK-B.COCompetitor analysis, valuation and peers

Denmark · DKK·Health Care›Pharmaceuticals: Major

Danish pharmaceutical company specializing in allergy immunotherapy tablets and injections.

Momentum weak 37
Mkt cap
$7.94B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$6.64M
20-day average traded
Fwd P/E
34.8×
forward earnings
ROIC−WACC
+19.3 pp
WACC 6.1%
Hurdle
-5 pp
Req g minus delivered
Next earnings
83 days
9 Feb 2027
Close · DKKDKK 243.00
1D-1.2%
1W-1.9%
1M+2.2%
3M+12.5%
6M-7.6%
YTD+6.3%
1Y+5.7%
ATR %2.6%
52w lowhigh10.5% off high

What ALK-abello A/S does

Danish pharmaceutical company specializing in allergy immunotherapy tablets and injections.

Patients take the tablets or injections for several years, so revenue builds from a base of ongoing treatments and reflects reimbursement rules in each country. Europe is the core, with the US a smaller but growing market. The Lundbeck Foundation, a Danish charitable holding, is the main shareholder.

Products and services

  • Sublingual immunotherapy tablets (Grazax, Acarizax)
  • Subcutaneous allergy injections
  • Allergy diagnostics

Customers

  • Allergists, physicians, patients with allergic rhi

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Allergy immunotherapy

What could go right

  • Immunotherapy tablet adoption growth
  • US launch expansion

What could go wrong

  • Reimbursement/pricing pressure in Europe
  • Narrow therapeutic focus

Moat: narrow (IP / patents, regulatory licence, process know-how). One of few global specialists in allergy immunotherapy with approvals across many markets.

Headquarters: Horsholm, Denmark · Founded: 1923 · Employees: 2,721

Named competitors

ALK-abello A/S at a glance

Size ALK-abello A/S (ALK-B.CO) is a Denmark Health Care company (Pharmaceuticals: Major) with a market value of $7.94B, the 17th largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 243.00 on 18 Nov 2026.

Performance Over six months the shares fell 7.6%, against +9.6% for the median peer and +6.3% for the Denmark market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 16.2% over the last twelve months (peer median +12.8%); the operating margin is 26.5% (peer median 13.8%).

Valuation It trades at 34.8× forward earnings against a peer median of 19.2× (5th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 19.3 points above its cost of capital (6.1% WACC).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 112ALK-B.CO 93
Six months, rebased to 100: ALK-abello A/S against the median of its 20 peers (local-currency closes).

ALK-abello A/S financials

Reported figures in DKK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueDKK 7.06BDKK 6.31BDKK 5.54BDKK 4.82BDKK 4.51B
Revenue growth—+14%+15%+7%—
Gross profitDKK 4.80BDKK 4.16BDKK 3.47BDKK 2.95BDKK 2.72B
EBITDADKK 2.22BDKK 1.98BDKK 1.36BDKK 909MDKK 707M
Net incomeDKK 1.40BDKK 1.20BDKK 815MDKK 486MDKK 335M
Free cash flowDKK 1.91BDKK 1.54BDKK 953MDKK 357MDKK 118M
Capital expenditureDKK 351MDKK 360MDKK 1.30BDKK 379MDKK 353M
Total debtDKK 478MDKK 418MDKK 1.19BDKK 765MDKK 696M

Quarterly statements and history in the cockpit →

ALK-abello A/S competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-40%-20%0%+20%GLENMARKALKS2196601607RYTMAMRXPTGX4151GRFKNSACORTPRAX4528002821CYTKIBRXBANB9926HLUN-AMDGLALK-B.CO6-month return →1-month return →
Up and to the right = strong over both horizons. ALK-abello A/S is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×GLENMARK2196PTGXKNSACORTMDGLALK-B.CORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ALK-abello A/S is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%GLENMARKALKS2196601607AMRXPTGX4151GRFKNSACORTALK-B.COGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ALK-abello A/S is the large dot.

ALK-abello A/S competitors and peer comparison

Head to head with its named competitors (ALK-B.CO vs AGY.L vs MRK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
ALK-abello A/S ALK-B.CO$7.94B-8%+16%26%34.8×7.3%
Allergy Therapeutics AGY.Ln/a-84%n/an/an/an/a
Merck & MRK$340B+23%+5%18%16.4×8.3%

How ALK-abello A/S compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ALK-abello A/S against its 20 peers (data as of 18 Nov 2026)
MeasureALK-B.COPeer medianRank in peer set
1-month return+2.2%+1.7%11th highest of 21
6-month return-7.6%+9.6%7th lowest of 21
Distance from 52-week high-10.5%-13.5%10th highest of 21
Revenue growth (TTM)+16.2%+12.8%10th highest of 21
Operating margin26.5%13.8%2nd highest of 20
Forward P/E34.8×19.2×5th most expensive of 14
Growth the price implies (Req g, 7 yrs)7.3%13.8%6th least demanding of 13
Growth delivered (Del g)+12.6%+9.0%3rd highest of 13
Hurdle (Req g minus delivered)-5.3 pp+3.7 pp6th least demanding of 13
ROIC minus cost of capital+19.3 pp+1.6 pp3rd highest of 18
EV / EBITDA23.7×18.9×5th most expensive of 13
Net debt / EBITDA-0.7×0.3×6th least indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%9.0×19.9%+5.8%
Shanghai Pharmaceuticals 601607.SSChina$8.23B0%+4%3%11.2×-10.1%+8.1%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a

Questions

Who are ALK-abello A/S's main competitors?
Named competitors: Stallergenes Greer (private or unlisted), Allergy Therapeutics (AGY.L), Merck & Co (allergy vaccines) (MRK). The cockpit's measured peer set (industry) also includes Glenmark Pharmaceuticals (GLENMARK.NS), Alkermes Public (ALKS), Shanghai Fosun Pharmaceutical (Group) (2196.HK), Shanghai Pharmaceuticals (601607.SS), Rhythm Pharmaceuticals (RYTM), Amneal Pharmaceuticals (AMRX).
Is ALK-abello A/S expensive compared with its peers?
On forward p/e it trades at 34.8× against a peer median of 19.2×, 5th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has ALK-abello A/S stock performed?
Over six months to 18 Nov 2026 the shares returned -7.6% against +9.6% for the median peer; over one year +5.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.